The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Disease Registry Based Approaches To Determining Molecular Risk Factors For Glaucoma Blindness, And Applying Them In Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$406,355.00
Summary
The Practitioner-Fellow has drawn together very large cohorts of patients from Australia, New Zealand and now internationally who have lost vision from Glaucoma and complications of Diabetes to determine the contributing factors. He has successfully identified major clinical and genetic risk factors for these diseases, and is now applying the knowledge to patients in early stages of disease, so that earlier and more aggressive treatment high risk individuals can lead to improved outcomes.
Molecular Imaging As A Critical Tool In Discovery Of The Basis Of Tumour Heterogeneity And Developing Novel Therapies To Overcome Therapeutic Resistance
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
Determining treatment options for cancer currently relies on the size and extent of tumour deposits on imaging, combined with a biopsy. However, this approach fails to recognise the ability of tumours to evolve components that are, or become, resistant to treatment. My laboratory uses advanced molecular imaging, targeted biopsies, animal models and genetic analysis to detect and understand the basis of such resistance and thereby develop new, targeted treatments to improve patient outcomes.
Neurobiology Of Childhood Speech And Language Disorders: Advancing Diagnosis, Prognosis And Management
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
Half a million Australian children have a speech/language disorder, tripling their changes of poor academic outcomes, limited employment options and social isolation. Current speech therapy is outdated, focusing on symptoms and ignoring important evidence on underlying aetiologies. I will transform detection, diagnosis and treatment of speech/language disorders to optimise patient outcomes, by identifying and translating findings on genes and brain pathways leading to these conditions.
Critical Infection: Ecological Solutions To Antibiotic Resistance
Funder
National Health and Medical Research Council
Funding Amount
$561,362.00
Summary
The applicant will apply new types of microbial data and diagnostic tools to early interventions in the critically ill and directly test their impact on clinical outcomes. He will also introduce novel therapies to restore antibiotic susceptibility to enteric bacteria and examine the clinical and microbiological effects of antibiotic decontamination of the critically ill in newly funded project grants. Overlapping research themes all link directly to his clinical and professional roles.
Translating Advances In Molecular Oncology Into Improved Care For Patients With Haematological Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$411,327.00
Summary
The purpose of my research is to develop and integrate into routine practice better treatment paradigms for patients with blood cancers – leukaemias, lymphomas, myeloma. My research seeks to (i) bring a new class of anti-cancer targeted therapy, inhibitors of Bcl-2, into routine care; (ii) discover the genetic changes that explain why slow growing lymphoid cancers change into rapidly fatal lymphomas; and (iii) integrate new molecular tests into the management of patients with acute leukaemia.
Translating Molecular Pathology Into Cancer Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$479,882.00
Summary
The aim of this research is focussed on translation of basic science through to the clinic by introducing novel cancer diagnostics and technologies. Other integral aims are to identify new changes in DNA and other cancer cell markers in patients, assess the clinical utility of these as biomarkers (surrogates of cancer behaviour) and to conduct novel clinical trials with newly identified molecular targets of cancer and new therapeutics and combinations to assess their efficacy.
Tackling Key Epidemiological And Basic Scientific Research Issues In Prion Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$401,109.00
Summary
Proposed Practitioner Fellowship research will simultaneously include epidemiological and basic scientific projects, emphasising human prion disease. Epidemiological research will involve large-scale studies to clarify genetic factors that influence susceptibility to developing prion disease, as well as clarify whether Alzheimer disease is transmissible, while basic scientific research will include determining the characteristics of the misfolded prion proteins causing neuronal disease.
Development Of Systemic Therapies To Improve Response And Prevent Resistance In The Treatment Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
This program of research utilises the unique resources at Melanoma Institute Australia (MIA) to understand the biology of prolonged response and resistance to novel drug therapies used in metastatic melanoma, a cancer that now leads the field in the discovery of new targets for therapeutic manipulation. This program also aims to create new methods to efficiently test and develop drug therapy combinations in humans to improve patient outcomes further or prevent metastatic melanoma altogether.
Multiple Sclerosis (MS) is an autoimmune disease often diagnosed in early adulthood. Outcomes very enormously, from mild to disabling. This fellowship supports research to improve outcome prediction using genetics and to examine different strategies to optimise treatment outcomes and safety. The main data source is MSBase, which tracks over 31000 people with MS globally and is based in the University of Melbourne's brain Centre at the Royal Melbourne Hospital.